At a tertiary care teaching hospital in New Delhi, researchers from the All India Institute of Medical Sciences spent six years quietly documenting a hidden threat to unborn children—one that most expecting mothers have never heard of. TORCH infections, a cluster of pathogens that includes toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus and others, cause barely noticeable symptoms in pregnant women but can devastate a developing fetus, leading to stillbirth, lifelong disability or severe birth defects.
This is a story that matters because maternal-fetal infections are preventable—yet they persist in regions where the public health response remains fragmented. Dr. Sudhahar Tamizhan and his team, including microbiologist Dr. Suneeta Meena as senior author and collaborator Dr. Rojaleen Das, analyzed laboratory records from 2019 through 2025, examining antibody patterns to understand who had been exposed to these pathogens and who had immunity. The work revealed something both encouraging and sobering: some prevention efforts are working, but a one-size-fits-all approach is failing pregnant women across the region.
The data showed that rubella vaccination initiatives in North India are having real impact. Researchers found consistently high immunity to rubella among patients tested, a direct result of vaccination campaigns. Yet a significant minority remained vulnerable not only to rubella but also to toxoplasmosis, which can be prevented through something as straightforward as careful hand washing, safe food preparation and careful handling of cat litter. The contrast is striking: one infection yields to vaccines; another requires behavioral change and food hygiene awareness.
Perhaps most striking was what the researchers discovered about cytomegalovirus. CMV exposure remained constant throughout the entire study period, indicating the virus circulates widely in the community. Unlike rubella, CMV receives far less public attention despite its prevalence. This matters because CMV is one of the leading infectious causes of congenital disability, yet many pregnant women don't know they should be screened for it.
"A 'one-size-fits-all' approach to TORCH testing may not always be the most effective strategy," Tamizhan explained. The insight is deceptively simple but carries real weight for public health planning. Rubella requires sustained vaccination coverage. Toxoplasmosis requires education about food safety and environmental exposure. CMV requires early identification and monitoring. Lumping them together under one screening protocol misses the specific vulnerabilities of different populations.
The team presented these findings at ASM Microbe 2026 in Washington, DC, as part of a broader push to inform public health policy beyond India's borders. Resource-limited settings across the world face similar gaps in congenital infection prevention, where surveillance data are sparse and prevention strategies are often borrowed wholesale from wealthier nations without adaptation. Tamizhan and his colleagues are already planning follow-up studies to understand age-specific and pregnancy-related risk factors, with particular focus on improving awareness of CMV and other congenital infections.
The researchers acknowledge the limitations: this is a single-center, retrospective study. Larger investigations across multiple hospitals will be needed to understand how regional variations shape infection risk. But the essential message is clear. Preventing congenital infections requires more than universal vaccination or generic screening protocols—it demands public health strategies tailored to what actually circulates in each community, informed by the kind of sustained surveillance these researchers have now begun to provide.